Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for asthma
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on asthma or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on asthma and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via email@example.com
• Depending on the FeNO cutoff, the likelihood of having asthma in people ages 5 years and older increases by 2.8 to 7.0 times given a positive FeNO test result. • FeNO is modestly more accurate in diagnosing steroid-naïve asthmatics, children (ages 5-18), and nonsmokers than other patients suspected to have asthma. • FeNO results can predict which patients will respond to inhaled corticosteroid therapy. • Using FeNO to manage long-term control medications including dose titration, weaning, and monitoring (...) asthma in people ages 5 years and older. Test performance is modestly better in steroid-naïve asthmatics, children, and nonsmokers than the general population with suspected asthma. Algorithms that include FeNO measurements can help in monitoring response to anti-inflammatory or long-term control medications, including dose titration, weaning, or treatment adherence. At this time, there is insufficient evidence supporting the measurement of FeNO in children under the age of 5 as a means
Effect of an Intervention to Promote Breastfeeding on Asthma, Lung Function, and Atopic Eczema at Age 16 Years: Follow-up of the PROBIT Randomized Trial Atopic diseases, including asthma and atopic eczema, are the most common chronic conditions of childhood.To investigate whether an intervention to promote prolonged and exclusive breastfeeding protects against asthma, atopic eczema, and low lung function in adolescence.Follow-up of the Promotion of Breastfeeding Intervention Trial (PROBIT (...) outcomes; secondary outcomes were self-reported asthma diagnosis ever, and wheezing and flexural eczema symptoms in the previous year.A total of 13 557 (79.5%) participants were followed up from September 15, 2012 to July 15, 2015. The intervention (7064 [79.7%]) and control (6493 [79.4%]) groups were similar at follow-up (3590 [50.8%] and 3391 [52.2%] male; mean [SD] age, 16.2 [0.6] and 16.1 [0.5] years, respectively). In the intervention group, 0.3% (21 of 7064) had flexural eczema on skin
Benralizumab (Fasenra) - For add-on maintenance treatment of patients with severe asthma aged 12 years and older, and with an eosinophilic phenotype Fasenra (benralizumab) 30 mg/mL Injection U.S. Department of Health and Human Services Search FDA Submit search Fasenra (benralizumab) 30 mg/mL Injection Fasenra Company: AstraZeneca Pharmaceuticals LP Application No.: 761070 Approval Date: 11/14/2017 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634
Fasenra - benralizumab - Asthma, severe eosinophilic benralizumab | CADTH.ca Find the information you need benralizumab benralizumab Last Updated: January 7, 2019 Result type: Reports Project Number: SR0561-000 Product Line: Generic Name: benralizumab Brand Name: Fasenra Manufacturer: AstraZeneca Canada Inc. Indications: Asthma, severe eosinophilic Manufacturer Requested Reimbursement Criteria 1 : For add-on maintenance treatment of adult patients with severe eosinophilic asthma who (...) are inadequately controlled with high-dose inhaled corticosteroids (ICS) and one or more additional asthma controller(s) (e.g., LABA), if one of the following clinical criteria are met: 1. Blood eosinophil count of 300 cells/L AND have experienced two or more clinically significant asthma exacerbations in the past 12 months, or 2. Blood eosinophil count of 150 cells/L and are treated chronically with oral corticosteroids (OCS). Submission Type: New Project Status: Active Biosimilar: No Date Recommendation
AsthmaAsthma - NICE CKS Share Asthma: Summary Asthma is a chronic inflammatory condition of the airways. The airways are hyper-responsive and constrict easily in response to a wide range of stimuli. This may result in coughing, wheezing, chest tightness, and shortness of breath. Asthma is a common condition. The British Lung Foundation states that 5.4 million people in the UK are receiving treatment for asthma. A diagnosis of asthma should be suspected in a person with: Wheeze, breathlessness (...) , chest tightness, and cough, particularly if symptoms are worse at night and in the early morning; occur in response to exercise, allergen exposure, and cold air; occur after taking non-steroidal anti-inflammatory drugs, or beta-blockers; occur in the absence of an upper respiratory tract infection. History of atopic disorder. Widespread wheeze (bilateral, predominantly expiratory). There is no single diagnostic test for asthma. Tests that can help support an asthma diagnosis include fractional
Breaking through Restricting Bottleneck for Better Asthma Control 29340274 2019 01 28 2450-131X 5 4 2017 Dec Journal of translational internal medicine J Transl Int Med Breaking through Restricting Bottleneck for Better Asthma Control. 192-193 10.1515/jtim-2017-0032 Zhu Ding D Department of Respiratory and Critical Care Medicine, Second Affiliated Hospital, Institute of Respiratory Diseases, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, China. Zhang Chao C Department (...) Diseases, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, China. eng Journal Article 2017 12 29 Poland J Transl Int Med 101673826 2224-4018 Conflict of Interest: None declared. 2018 1 18 6 0 2018 1 18 6 0 2018 1 18 6 1 epublish 29340274 10.1515/jtim-2017-0032 jtim-2017-0032 PMC5767707 Am J Respir Crit Care Med. 2010 Jan 15;181(2):116-24 19815809 J Asthma. 2016;53(1):94-100 26383773 Respir Med. 2006 Jul;100(7):1139-51 16713224 J Pediatr Pharmacol Ther. 2017 Jul-Aug;22(4):293-299
Evaluation of anxiety and depression in mothers of children with asthmaAsthma is the most common chronic disease in childhood. Parents have an important role in managing asthma in children. Studies have shown a higher degree of depression and anxiety and lower family performance in mothers of asthmatic children in comparison with the control group.The aim of this study was to evaluate the parenting styles and also depression, anxiety and stress parameters in mothers of children (...) with asthma.This case-control study was performed on 45 mothers of 3 to 15 years old asthmatic children in the allergy clinic of Mashhad University of Medical Sciences, Mashhad, Iran, during the years of 2014 to 2016. The control group was 45 mothers of non-asthmatic children who were matched for the age of their children with the case group in the same population. The parenting styles, as well as depression and anxiety of mothers were evaluated using parenting scales, and the depression-anxiety-stress scales
Asthma. Asthma-one of the most common chronic, non-communicable diseases in children and adults-is characterised by variable respiratory symptoms and variable airflow limitation. Asthma is a consequence of complex gene-environment interactions, with heterogeneity in clinical presentation and the type and intensity of airway inflammation and remodelling. The goal of asthma treatment is to achieve good asthma control-ie, to minimise symptom burden and risk of exacerbations. Anti-inflammatory (...) and bronchodilator treatments are the mainstay of asthma therapy and are used in a stepwise approach. Pharmacological treatment is based on a cycle of assessment and re-evaluation of symptom control, risk factors, comorbidities, side-effects, and patient satisfaction by means of shared decisions. Asthma is classed as severe when requiring high-intensity treatment to keep it under control, or if it remains uncontrolled despite treatment. New biological therapies for treatment of severe asthma, together
Stormy weather: a retrospective analysis of demand for emergency medical services during epidemic thunderstorm asthma. To describe the demand for emergency medical assistance during the largest outbreak of thunderstorm asthma reported globally, which occurred on 21 November 2016.A time series analysis was conducted of emergency medical service caseload between 1 January 2015 and 31 December 2016. Demand during the thunderstorm asthma event was compared to historical trends for the overall (...) November, compared with a daily average of 52 during the historical period. After adjustment for temporal trends, thunderstorm asthma was associated with a 42% (95% confidence interval 40% to 44%) increase in overall caseload for the emergency medical service and a 432% increase in emergency medical attendances for acute respiratory distress symptoms. Emergency transports to hospital increased by 17% (16% to 19%) and time critical referrals from general practitioners increased by 47% (21% to 80
Breathing training for dysfunctional breathing in asthma: taking a multidimensional approach Various breathing training programmes may be helpful for adults with asthma. The main therapeutic aim for many of these programmes is the correction of dysfunctional breathing. Dysfunctional breathing can be viewed practically as a multidimensional entity with the three key dimensions being biochemical, biomechanical and psychophysiological. The objectives of this review are to explore how each (...) of these dimensions might impact on asthma sufferers, to review how various breathing therapy protocols target these dimensions and to determine if there is evidence suggesting how breathing therapy protocols might be optimised. Databases and reference lists of articles were searched for peer-reviewed English language studies that discussed asthma or dysfunctional breathing and various breathing therapies. Biochemical, biomechanical and psychophysiological aspects of dysfunctional breathing can all potentially
International Variation in Asthma and Bronchiolitis Guidelines Guideline recommendations for the same clinical condition may vary. The purpose of this study was to determine the degree of agreement among comparable asthma and bronchiolitis treatment recommendations from guidelines.National and international guidelines were searched by using guideline databases (eg, National Guidelines Clearinghouse: December 16-17, 2014, and January 9, 2015). Guideline recommendations were categorized as (1 (...) ) recommend, (2) optionally recommend, (3) abstain from recommending, (4) recommend against a treatment, and (5) not addressed by the guideline. The degree of agreement between recommendations was evaluated by using an unweighted and weighted κ score. Pairwise comparisons of the guidelines were evaluated similarly.There were 7 guidelines for asthma and 4 guidelines for bronchiolitis. For asthma, there were 166 recommendation topics, with 69 recommendation topics given in ≥2 guidelines. For bronchiolitis
Effectiveness and Safety of Bronchial Thermoplasty in Management of Asthma Comparative Effectiveness Review Number 202 Effectiveness and Safety of Bronchial Thermoplasty in Management of Asthma eComparative Effectiveness Review Number 202 Effectiveness and Safety of Bronchial Thermoplasty in Management of Asthma Prepared for: Agency for Healthcare Research and Quality U.S. Department of Health and Human Services 5600 Fishers Lane Rockville, MD 20857 www.ahrq.gov Contract No. 290-2015-00005-I (...) and safety of bronchial thermoplasty (BT), a procedure that uses heat to remove muscle tissue from the airways of adults with moderate to severe asthma. BT is usually given as three treatments 3 weeks apart. Key Messages • BT along with standard medical management, compared to medical management alone, may improve asthma control and quality of life, but evidence is insufficient to determine impact on asthma exacerbations. • BT along with standard medical management, compared to a similar procedure
Exemplar clinical pathways for a stratified approach to severe asthma The Academy of Medical Sciences 4 ? ? ? ? ? ? ? The Academy of Medical Sciences 5 The Academy of Medical Sciences 6 The Academy of Medical Sciences 7 Introduction to a stratified approach ? ? ? ? The Academy of Medical Sciences 8 The Academy of Medical Sciences 9 ? ? ? The Academy of Medical Sciences 10 The Academy of Medical Sciences 11 The Academy of Medical Sciences 12 The Academy of Medical Sciences 13 Adopting
Nebulized Hypertonic Saline for Asthma in Adults and Children: Clinical Effectiveness Nebulized Hypertonic Saline for Asthma in Adults and Children: Clinical Effectiveness | CADTH.ca Find the information you need Nebulized Hypertonic Saline for Asthma in Adults and Children: Clinical Effectiveness Nebulized Hypertonic Saline for Asthma in Adults and Children: Clinical Effectiveness Published on: October 31, 2017 Project Number: RA0937-000 Product Line: Research Type: Devices and Systems Report